prikaz prve stranice dokumenta Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
Supportive care in cancer, 24 (2016), 11; 4495-4502. https://doi.org/10.1007/s00520-016-3287-y
Srdić, Dražena; Pleština, Sanja; Šverko- Peternac, Ana; Nikolac, Nora; Šimundić, Ana- Maria; Samaržija, Miroslav

Cite this document

Srdić, D., Pleština, S., Šverko Peternac, A., Nikolac, N., Šimundić, A. M. & Samaržija, M. (2016). Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Supportive care in cancer, 24. (11), 4495-4502. doi: 10.1007/s00520-016-3287-y

Srdić, Dražena, et al. "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value." Supportive care in cancer, vol. 24, no. 11, 2016, pp. 4495-4502. https://doi.org/10.1007/s00520-016-3287-y

Srdić, Dražena, Sanja Pleština, Ana Šverko Peternac, Nora Nikolac, Ana Maria Šimundić and Miroslav Samaržija. "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value." Supportive care in cancer 24, no. 11 (2016): 4495-4502. https://doi.org/10.1007/s00520-016-3287-y

Srdić, D., et al. (2016) 'Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value', Supportive care in cancer, 24(11), pp. 4495-4502. doi: 10.1007/s00520-016-3287-y

Srdić D, Pleština S, Šverko Peternac A, Nikolac N, Šimundić AM, Samaržija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Supportive care in cancer [Internet]. 2016 [cited 2024 November 25];24(11):4495-4502. doi: 10.1007/s00520-016-3287-y

D. Srdić, S. Pleština, A. Šverko Peternac, N. Nikolac, A. M. Šimundić and M. Samaržija, "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value", Supportive care in cancer, vol. 24, no. 11, pp. 4495-4502, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:969354. [Accessed: 25 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
AuthorDražena Srdić
AuthorSanja Pleština
AuthorAna Šverko- Peternac
AuthorNora Nikolac
MBZ: 266202
AuthorAna- Maria Šimundić
MBZ: 235703
AuthorMiroslav Samaržija
MBZ: 146943
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Cancer cachexia and sarcopenia are frequently observed in non-small lung cancer patients and associated with poor survival. The purpose of our study was to evaluate prevalence of cachexia and sarcopenia in patients with diagnosed advanced NSCLC and their impact on chemotherapy toxicity and time to disease progression, as well as predictive value of several biochemical markers. One hundred patients with advanced IIIB or IV stage of NSCLC that were to start with systemic chemotherapy were recruited in the study. We provided anthropometric and biochemical data and body composition measurements for each patient. Muscle mass was measured by the analysis of electronically stored CT images using lumbar vertebral landmark (L3). Measured muscle area in this region correspond to whole-body tissue quantities. The prevalence of cachexia in our study was 69%, and sarcopenia was present in 47% of patients. We found statistically significant difference between CRP, IL-6 and albumin concentration in cachectic patients and non-cachectic patients. In our study, cachexia and sarcopenia were not predictors of chemotoxicity and survival, but albumin concentration has been shown to be the predictive factor of both chemotoxicity and survival. Biochemical parameters, such as CRP and albumin level have shown to be of more important predictive value in chemotherapy toxicity and survival probability than cachexia and sarcopenia.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleSupportive care in cancer
Numberingvol. 24, no. 11, pp. 4495-4502
p-ISSN0941-4355
DOIhttps://doi.org/10.1007/s00520-016-3287-y
URN:NBNurn:nbn:hr:184:969354
Publication2016
Document URLhttp://bib.irb.hr/834213
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-02-09 08:16:35